The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
J | Antiinfectives for systemic use | |
2
|
J05 | Antivirals for systemic use | |
3
|
J05A | Direct acting antivirals | |
4
|
J05AR | Antivirals for treatment of HIV infections, combinations | |
5
|
J05AR14 | Darunavir and cobicistat |
| Active Ingredient |
|---|
|
Darunavir is an inhibitor of the dimerisation and of the catalytic activity of the HIV-1 protease. It selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus infected cells, thereby preventing the formation of mature infectious virus particles. Cobicistat is a mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily. Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism. |
| Document | Type | Information Source | |
|---|---|---|---|
| PREZCOBIX Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| REZOLSTA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.